News
Brand Change Announcement: AegirBio AB has officially changed its name to Magnasense AB. The new website, www.magnasense.com, launched on 9 July 2024, with redirects from www.aegirbio.com.
Magnasense on track in RADx project
Magnasense AB is pleased to share an update on its ongoing product development under the RADx (Rapid Acceleration of Diagnostics) initiative. As the company approaches the November deadline its magnetic test strips have shown good performance with the MagniaReader platform, reflecting progress in the project.
Currently, Magnasense is working closely with Digital Health Solutions (DHS to finalize the firmware of the prototype Reader to meet the necessary sensitivity requirements. This collaboration is critical to ensuring the system operates as intended, and the companies remain fully committed to supporting these efforts both from a development and financial standpoint.
The project is now entering a critical stage, with internal validation (Milestone 3) scheduled for the second half of October. Upon successful completion, the prototype Readers and test kits will be shipped to an external validation lab, achieving Milestone 4. These key milestones are the company’s primary focus as it works toward completing this phase of the RADx initiative.
"The Magnasense and DHS teams are committed to meeting both the project timelines and performance goals," said Marco Witteveen, CEO of Magnasense. "Our objective is to demonstrate the reliability of our solution and gain approval from the RADx committee to advance the project. We will continue to provide updates as we progress."
